Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303985 | 0.73 | GLRA3 (0.43) | KDM4EALDH1A1GAACA2TDP1 | |
| SCHEMBL12245662 | 0.72 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDGAACA2 | |
| SCHEMBL11954931 | 0.72 | CA2 (0.39) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL9277537 | 0.69 | KDM4E (0.37) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL14336787 | 0.69 | CYP1A2 (0.35) | ALDH1A1CA2TSHRTDP1 | |
| SCHEMBL14336995 | 0.67 | — | — | |
| SCHEMBL16556090 | 0.67 | KDM4E (0.34) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL9277458 | 0.67 | KDM4E (0.34) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL11955172 | 0.66 | MAOA (0.44) | ALDH1A1CA2TSHRTDP1 | |
| SCHEMBL15746201 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-7312246-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | KDM4E 2715/4885ALDH1A1 3689/4885HPGD 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.